Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis

References

• Anderson J R, Armitage J O, Weisenburger D D. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998; 9: 717–720
   PubMed Web of Science ®Google Scholar
• Kang Y K, Kim B S, Kim T W, Ryu M H, Lee S S, Ryoo B Y, et al. Clinicopathologic characteristics of Korean non-Hodgkin's lymphomas based on REAL classification. J Korean Cancer Assoc 1999; 31: 641–652
   Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan W C, Connors J M, Campo E, Fisher R I, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947
   PubMed Web of Science ®Google Scholar
• Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78–84
   PubMed Web of Science ®Google Scholar
• Hans C P, Weisenburger D D, Greiner T C, Gascoyne R D, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282
   PubMed Web of Science ®Google Scholar
• Jacob M C, Piccinni M P, Bonnefoix T, Sotto M F, Couderc P, Bensa J C, et al. T lymphocytes from invaded lymph nodes in patients with B-cell-derived non-Hodgkin's lymphoma: reactivity toward the malignant clone. Blood 1990; 75: 1154–1162
   PubMed Web of Science ®Google Scholar
• Lippman S M, Spier C M, Miller T P, Slymen D J, Rybski J A, Grogan T M. Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. Mod Pathol 1990; 3: 361–367
   PubMed Web of Science ®Google Scholar
• Ansell S M, Stenson M, Habermann T M, Jelinek D F, Witzig T E. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol 2001; 19: 720–726
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Viglietta V, Hafler D A. Human CD4+CD25+ regulatory T cells. Semin Immunol 2004; 16: 89–98
   PubMed Web of Science ®Google Scholar
• Piccirillo C A, Shevach E M. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 2004; 16: 81–88
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151–1164
   PubMed Web of Science ®Google Scholar
• Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol 2003; 81: 331–371
   PubMed Web of Science ®Google Scholar
• Li B, Samanta A, Song X, Furuuchi K, Iacono K T, Kennedy S, et al. FOXP3 ensembles in T-cell regulation. Immunol Rev 2006; 212: 99–113
   PubMed Web of Science ®Google Scholar
• Curotto de Lafaille M A, Lafaille J J. CD4(+) regulatory T cells in autoimmunity and allergy. Curr Opin Immunol 2002; 14: 771–778
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057–1061
   PubMed Web of Science ®Google Scholar
• Beyer M, Schultze J L. Regulatory T cells in cancer. Blood 2006; 108: 804–811
   PubMed Web of Science ®Google Scholar
• Liyanage U K, Moore T T, Joo H G, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 2756–2761
   PubMed Web of Science ®Google Scholar
• Woo E Y, Chu C S, Goletz T J, Schlienger K, Yeh H, Coukos G, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 4766–4772
   PubMed Web of Science ®Google Scholar
• Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003; 98: 1089–1099
   PubMed Web of Science ®Google Scholar
• Schaefer C, Kim G G, Albers A, Hoermann K, Myers E N, Whiteside T L. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005; 92: 913–920
   PubMed Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Fox B C, Colomo L, Martinez A, Roncador G, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108: 2957–2964
   PubMed Web of Science ®Google Scholar
• Lee A M, Clear A J, Calaminici M, Davies A J, Jordan S, MacDougall F, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006; 24: 5052–5059
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvado M T, Bosch R, Garcia J F, Jaen J, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005; 11: 1467–1473
   PubMed Web of Science ®Google Scholar
• Gatter K CWR. Diffuse large B-cell lymphoma. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid tissue: World Health Organization Classification of Tumours, E S Jaffe, N L Harris, H Stein, J W Vardiman. IARC Press, Lyon, France 2001; 171–174
   Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric-estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170
   PubMedGoogle Scholar
• Cox D R. Regression models and life-tables. J R Stat Soc 1972; 34: 187–220
   Google Scholar
• O'Garra A, Vieira P L, Vieira P, Goldfeld A E. IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage. J Clin Invest 2004; 114: 1372–1378
   PubMed Web of Science ®Google Scholar
• Jarnicki A G, Lysaght J, Todryk S, Mills K H. Suppression of antitumor immunity by IL-10 and TGF-β-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 2006; 177: 896–904
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212: 8–27
   PubMed Web of Science ®Google Scholar
• Coffer P J, Burgering B M. Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol 2004; 4: 889–999
   PubMed Web of Science ®Google Scholar
• Fontenot J D, Gavin M A, Rudensky A Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330–336
   PubMed Web of Science ®Google Scholar
• Huang C T, Workman C J, Flies D, Pan X, Marson A L, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity 2004; 21: 503–513
   PubMed Web of Science ®Google Scholar
• Antony P A, Paulos C M, Ahmadzadeh M, Akpinarli A, Palmer D C, Sato N, et al. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol 2006; 176: 5255–5266
   PubMed Web of Science ®Google Scholar
• Kabelitz D, Wesch D, Oberg H H. Regulation of regulatory T cells: role of dendritic cells and toll-like receptors. Crit Rev Immunol 2006; 26: 291–306
   Google Scholar
• Lim H W, Hillsamer P, Banham A H, Kim C H. Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol 2005; 175: 4180–4183
   PubMed Web of Science ®Google Scholar
• Zhao D M, Thornton A M, DiPaolo R J, Shevach E M. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 2006; 107: 3925–3932
   PubMed Web of Science ®Google Scholar
• Yang Z Z, Novak A J, Stenson M J, Witzig T E, Ansell S M. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107: 3639–3646
   PubMed Web of Science ®Google Scholar
• Yang Z Z, Novak A J, Ziesmer S C, Witzig T E, Ansell S M. Attenuation of CD8+T-cell function by CD4+CD25+regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2006; 66: 10145–10152
   PubMed Web of Science ®Google Scholar
• Hilchey S P, De A, Rimsza L M, Bankert R B, Bernstein S H. Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25− and CD4+CD25− T cells. J Immunol 2007; 178: 4051–4061
   PubMed Web of Science ®Google Scholar